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A comprehensive transcript index of the human genome generated using microarrays and computational approaches <p>Computational and microarray-based experimental approaches were used to generate a comprehensive transcript index for the human  genome. Oligonucleotide probes designed from approximately 50,000 known and predicted transcript sequences from the human genome  were used to survey transcription from a diverse set of 60 tissues and cell lines using ink-jet microarrays. Further, expression activity over  at least six conditions was more generally assessed using genomic tiling arrays consisting of probes tiled through a repeat-masked version  of the genomic sequence making up chromosomes 20 and 22.</p>
Abstract
Background:  Computational and microarray-based experimental approaches were used to
generate a comprehensive transcript index for the human genome. Oligonucleotide probes
designed from approximately 50,000 known and predicted transcript sequences from the human
genome were used to survey transcription from a diverse set of 60 tissues and cell lines using ink-
jet microarrays. Further, expression activity over at least six conditions was more generally
assessed using genomic tiling arrays consisting of probes tiled through a repeat-masked version of
the genomic sequence making up chromosomes 20 and 22.
Results: The combination of microarray data with extensive genome annotations resulted in a set
of 28,456 experimentally supported transcripts. This set of high-confidence transcripts represents
the first experimentally driven annotation of the human genome. In addition, the results from
genomic tiling suggest that a large amount of transcription exists outside of annotated regions of
the genome and serves as an example of how this activity could be measured on a genome-wide
scale.
Conclusions:  These data represent one of the most comprehensive assessments of
transcriptional activity in the human genome and provide an atlas of human gene expression over
a unique set of gene predictions. Before the annotation of the human genome is considered
complete, however, the previously unannotated transcriptional activity throughout the genome
must be fully characterized.
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Background
The completion of the sequencing of the human, mouse and
other genomes has enabled efforts to extensively annotate
these genomes using a combination of computational and
experimental approaches. Generating a comprehensive list of
transcripts coupled with basic information on where the dif-
ferent transcripts are expressed is an important first step
towards annotating a genome once it has been fully
sequenced. The task of identifying the transcribed regions of
a sequenced genome is complicated by the fact that tran-
scripts are composed of multiple short exons that are distrib-
uted over much larger regions of genomic DNA. This
challenge is underscored by the widely divergent predictions
of the number of genes in the human genome. For example,
direct clustering of human expressed sequence tag (EST)
sequences has predicted as many as 120,000 genes [1],
whereas sampling and sequence-similarity-based methods
have predicted far lower numbers, ranging from 28,000 to
35,000 genes [2-5], and a hybrid approach has suggested an
intermediate number [6]. Furthermore, the availability of a
completed draft sequence of the human genome has yielded
neither a proven method for gene identification nor a defini-
tive count of human genes. Two initial analyses of the human
genome sequence that used strikingly different methods both
suggested the human genome contains 30,000 to 40,000
genes [2,3]. However, a direct comparison of the predicted
genes revealed agreement in the identification of well-charac-
terized genes but little overlap of the novel predictions. Spe-
cifically, 84% of the RefSeq transcripts agreed with fewer
than 20% of the predicted transcripts matching between the
two analyses. This result suggests that, individually, these
datasets are incomplete and that the human genome poten-
tially contains substantially more unidentified genes [7].
Several recent studies have highlighted the limitations of rely-
ing solely on computational approaches to identify genes in
the draft of the human genome [8-13]. Furthermore, substan-
tial experimental data from direct assays of gene expression
provide evidence for many genes that would not have been
recognized in the analyses just mentioned. Saha and col-
leagues used a new LongSAGE technology to provide strong
evidence that there are thousands of genes left to be discov-
ered in the human genome [9]. Specifically, they sequenced
over 27,000 tags from a human colorectal cell line that col-
lapsed down to 5,641 unique groups. Interestingly, only 61%
(3,419) of the tags matched known or predicted genes,
whereas 10% (575) matched novel internal exons and 14%
(803) appear to represent completely novel genes [9]. They
extrapolate from these data to predict as many as 7,500 exons
from previously unrecognized genes. A recent analysis by
Camargo et al. [8] also indicates that we are far from defining
a complete catalog of human genes based on the analysis of
700,000 ORESTES (Open Reading Frame ESTs) that were
recently released into GenBank. Finally, Kapranov and col-
leagues recently constructed genome-tiling arrays for human
chromosomes 21 and 22 to comprehensively query
transcription activity over 11 human tissues and cell lines
[10]. They detected significant, widespread expression activ-
ity over a substantial proportion of these chromosomes out-
side of all known and predicted gene regions.
Most current methods in widespread use for identifying novel
genes in genomic sequence depend on sequence similarity to
expressed sequence and protein data. For example, ab initio
prediction programs operate by recognizing coding potential
in stretches of genomic sequence, where the recognition capa-
bility of these programs depends on a training set of known
coding regions [14]. Therefore, genes identified by ab initio
prediction programs or assembled from EST data are also
inaccurate or incomplete much of the time [10-12]. While ab
initio prediction programs perform well at identifying known
genes, predictions that do not use existing expressed
sequence and protein data often miss exons, incorrectly iden-
tify exon boundaries, and fail to accurately detect the 3' and 5'
untranslated regions UTRs [14]. Similarly, EST data may be
biased towards the 3' or 5' UTR [13]. These deficiencies are
addressed in full-length gene cloning strategies [13], but clon-
ing is still a laborious process which could be accelerated if we
were able to start from a more accurate view of a putative gene
[13].
Recently, several groups have used microarrays to test com-
putational gene predictions experimentally and to tile across
genomic sequence to discover the transcribed regions in the
human and other genomes [10-12,15-17]. These array-based
approaches detected widespread transcriptional activity out-
side of the annotated gene regions in the human, Arabidopsis
thaliana and Escherichia coli genomes. The recent sequenc-
ing and analysis of the mouse genome indicates extensive
homology between intergenic regions of the human and
mouse genomes, further highlighting the potential for other
classes of transcribed regions [18]. Interestingly, recent tiling
data suggests that many of these conserved intergenic regions
are transcribed [15,16].
In the study reported here, we describe hybridization results
generated from two large microarray-based gene-expression
experiments involving predicted transcript arrays spanning
the entire human genome and a comprehensive set of
genomic tiling arrays for human chromosomes 20 and 22.
mRNA samples collected from a diversity of conditions were
amplified using a strand-specific labeling protocol that was
optimized to generate full-length copies of the transcripts.
Analyses of the resulting hybridization data from both sets of
arrays revealed widespread transcriptional activity in both
known or high-confidence predicted genes, as well as regions
outside current annotations. The results from this analysis
are summarized with respect to published genes on chromo-
somes 20 and 22 in addition to our own extensive set of
genome alignments and gene predictions. Combining compu-
tational and experimental approaches has allowed us to gen-
erate a comprehensive transcript index for the humanhttp://genomebiology.com/2004/5/10/R73 Genome Biology 2004,     Volume 5, Issue 10, Article R73       Schadt et al. R73.3
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genome, which has been a valuable resource for guiding our
array design and full-length cloning efforts. In addition, the
expression data from the 60 conditions provides a compre-
hensive atlas of human gene expression over a unique set of
gene predictions [19].
Results
Generating a comprehensive transcript index of the 
human genome
Figure 1 illustrates the process we used to generate a compre-
hensive transcript index (CTI) for the human genome that
represents just over 28,000 known and predicted transcripts
with some level of experimental validation. The first step in
this process was to generate a 'primary transcript index' (PTI)
by mapping a comprehensive set of computationally and
experimentally derived annotations onto the genomic
sequence. The computational predictions include the output
of gene-finding algorithms and protein similarities, while the
experimentally derived alignments are based on ESTs, serial
analysis of gene expression (SAGE), and full-length cDNAs.
The resulting list of transcripts in the PTI can be loosely
ranked or classified into different categories, ranging from
high confidence to low confidence, on the basis of the level of
underlying experimental support. The advantages of a PTI are
that the computations can be performed on a genome-wide
scale and it incorporates the massive amounts of publicly
available EST, SAGE and cDNA sequence data. However, the
resulting transcript index has two significant limitations.
First, the ab initio gene-finding algorithms tend to have a
high false-positive rate when applied at a low-stringency set-
ting to cast as broad a discovery net as possible. Second, gene-
finding algorithms are trained on known protein-coding
genes, which may limit their ability to detect truly novel
classes of transcribed sequences.
The second step towards the CTI is the use of two different
types of microarrays to address these limitations (Figure 1).
First, predicted transcript arrays (PTA) were used to deter-
mine experimentally which of the lower-confidence predic-
tions in the PTI were likely to represent real transcripts.
Second, genomic tiling arrays were used to survey transcrip-
tional activity in a completely unbiased and comprehensive
fashion. As shown in Figure 1, the CTI plays a central part in
the subsequent design of screening arrays. These are used to
monitor RNA levels for all the transcripts across a large
number of diverse conditions to begin the process of assign-
ing biological functions to novel genes based on co-regulation
with known genes [20]. The CTI is also used to design exon/
junction arrays that can be used to discover and monitor
alternative splicing across different tissues and stages of
development [21].
Generating a PTI
To generate the PTI, three distinct computational analysis
steps were executed in parallel: predictions based on similar-
ity to expressed sequences from human and mouse; predic-
tions based on similarity to all known proteins; and ab initio
gene predictions. The process resulted in mapping 91% of the
well characterized genes found in the RefSeq database [22], a
percentage consistent with initial genome annotation results
[2,3]. The mapping results were generated by collapsing over-
lapping gene models and regions of similarity to define locus
projections, which comprise the distinct transcribed regions
making up our PTI. While the reliance on gene predictions
and protein alignments biases the PTI towards protein-cod-
ing genes, the alignment of all expressed sequences should
represent many of the non-coding genes reported to date. A
comprehensive index of non-coding genes would require til-
ing arrays, as described later.
All locus projections were classified into one of eight catego-
ries on the basis of the level of underlying evidence from
expressed sequence similarity, protein similarity and ab ini-
tio predictions. The categories, in decreasing order of sup-
port, are as follows: (1) known genes, taken as the set of 11,214
human genes represented in the RefSeq database when the
arrays were designed; (2) ab initio gene models with
expressed sequence and protein support; (3) ab initio gene
models with expressed sequence support; (4) ab initio gene
models with protein support; (5) alignments of expressed
sequence and protein data; (6) alignments of expressed
sequence data, requiring at least two overlapping expressed
sequences; (7) ab initio gene models with no expressed
sequence or protein support; and (8) alignments of protein
data. Because of the limitations discussed in the previous sec-
tion, we considered predictions with a single line of evidence
(categories 6-8) as low confidence.
Table 1 provides summaries resulting from a comparison
between our PTI and the published Sanger Institute data for
chromosomes 20 and 22 [23,24]. Our locus projections over-
lap 1,177 of 1,297 (91%) Sanger genes on chromosome 20 and
854 of 936 (91%) Sanger genes on chromosome 22, and our
predicted exons overlap 7,306 of 7,556 (97%) and 4,819 of
5,014 (96%) total Sanger chromosome 20 and 22 exons,
respectively. This comparison highlights the fact that our
annotations result in the detection of both genes and exons in
genomic sequence with high sensitivity.
Predicted transcript arrays
We previously described a high-throughput, experimental
procedure to validate predicted exons and assemble exons
into genes by using co-regulated expression over a diversity of
conditions [11]. Here we employ a similar strategy over the
entire genome by hybridizing RNA from 60 diverse tissue and
cell-line samples to a set of arrays designed from the PTI. For
a complete list of the transcripts represented on the predicted
transcript arrays and 60 tissues and cell lines hybridized to
these arrays (see Additional data files 1 and 2). We designed
two probes per exon, where possible, for exons containing the
highest-scoring probes as described in the methods from eachR73.4 Genome Biology 2004,     Volume 5, Issue 10, Article R73       Schadt et al. http://genomebiology.com/2004/5/10/R73
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transcript in our PTI set (on average, a total of four probes per
transcript). This was done to balance the poor specificity of ab
initio gene-finding algorithms [14,25,26] against the signifi-
cant microarray costs associated with large-scale gene-
expression experiments. The resulting hybridization data
provides experimental validation of those low-confidence
predicted genes that are either unsupported or minimally
supported by existing EST data, thereby providing a means of
determining which transcripts are included in the CTI.
Summary of predicted transcript validation on 
chromosomes 20 and 22
We used an enhanced version of a previously described gene-
detection algorithm to analyze the predicted transcript array
dataset [11]. Basically, the hybridization data from probes
each transcript from the PTI were examined to identify those
transcripts with probes that appear to be more highly corre-
lated over the 60 diverse conditions. Transcripts with probes
that behaved similarly over the different conditions tested
were considered to be expression-validated genes (EVGs).
Unlike our original algorithm that used Pearson correlations
to group similarly behaving probes, our enhanced algorithm
incorporated a probe-specific model to assess the most likely
set of probes making up a transcriptional unit [27] (see
Materials and methods for details). We used the extensive
publicly available annotations on chromosomes 20 and 22 to
assess the sensitivity and specificity of our array-based detec-
tion procedure.
The sensitivity of our procedure was assessed by computing
the EVG detection rate for those Sanger genes that overlap
predictions (locus projections) represented in our PTI (Table
2). The average detection rate for our locus projections on
chromosomes 20 and 22 is approximately 70% for those over-
lapping Sanger genes and just over 80% for those locus pro-
jections derived from RefSeq alignments (locus category =
A process to generate a comprehensive transcript index (CTI) for the human genome Figure 1
A process to generate a comprehensive transcript index (CTI) for the human genome. The first step is the assembly of a comprehensive set of annotations 
to generate a predicted transcript index (PTI). Sets of microarrays capable of monitoring the transcription activity over the entire genome can then be 
designed on the basis of the PTI. The different microarray types that can be used in this process include predicted transcript arrays (PTA), exon junction 
arrays (EJA) [21] and genome tiling arrays (GTA). After hybridizing a diversity of conditions onto these arrays, the transcription data are processed to 
identify a comprehensive set of transcripts (the CTI) and associated probes that are capable of querying all forms of transcripts that may exist in the 
genome. This set of probes comprises a focused set of microarrays that can be used in more standard microarray-based experiments.
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known) that represent Sanger genes. A true positive in this
instance was defined as an expression-verified gene contain-
ing at least two probes, where at least one of the probes was
contained within the exon of a Sanger or RefSeq gene.
This 20% false-negative rate is the result of a complex mix-
ture of issues, including limitations in our EVG-detection
algorithm, limitations in the probe design step, lack of expres-
sion in the conditions profiled, and/or alternative splicing
events. While the EVG-detection algorithm provides an effi-
cient method to assemble probes into transcript units, the
detection capabilities of this model could be expected to
improve as the number of samples and the number of probes
targeting any given transcript increases. The use of four
probes per predicted transcript was determined to be suffi-
cient for detection of most transcripts, as supported by the
overall detection rate of known genes, although in many cases
the probe design step was limited by our ability to find four
high-quality probes per transcript. For many transcripts,
there were not four nonoverlapping probes predicted to have
good hybridization characteristics for the microarray experi-
ment carried out here. The 60 samples were chosen to repre-
sent a broad array of tissue types, as an exhaustive list of
human tissues is impossible to obtain. Because no replicate
tissues/cell lines were run for any of the 60 chosen samples,
we relied on the replication inherent in monitoring the same
transcripts over 60 different conditions. In this case, genes
expressed in multiple samples provide the replication neces-
sary to increase our confidence in the detections. However,
there are clear limitations in not replicating tissues/cell lines,
as genes may be expressed in only a single condition or may
be switched on only under certain physiological conditions or
only during a certain stages of development. In such cases, we
would have reduced power to detect these genes.
Genes in the lower-confidence categories of our PTI annota-
tions, which are not typically considered genes by Sanger,
were detected at a significantly reduced rate. Interestingly, of
the 337 (188 +149) higher-confidence transcripts on chromo-
somes 20 and 22 that did not intersect with Sanger genes, 47
(or 14%) were detected as EVGs (Table 2). These transcripts
represent potential novel transcripts on these two highly
characterized chromosomes.
However, before we can make claims to the discovery poten-
tial for this method over the entire genome, we need to assess
the false-positive detection rates. To this end, we defined as
false positives all detections made in regions with support by
only a single gene model that fell outside Sanger-annotated
genes on chromosomes 20 and 22. Applying this definition
Table 1
Comparison of locus projections in the PTI on chromosomes 20 and 22 to Sanger-annotated genes
Sanger 
chromosome 
20, genes
Non-Sanger 
chromosome 
20, genes
Sanger 
chromosome 
22, genes
Non-Sanger 
chromosome 
22, genes
Sanger genes 
(including pseudogenes)
1,297 936
Locus projection categories
High-confidence categories RefSeq 676 (30) 8 375 (47) 12
Ab initio + expressed sequence + 
protein
336 (63) 10 285 (127) 10
Ab initio + expressed sequence 38 (2) 96 28 (7) 74
Ab initio + protein 28 (11) 37 31 (18) 29
Expressed sequence + protein 38 (30) 37 36 (30) 24
Low-confidence categories Ab initio 22 (4) 674 50 (21) 362
Protein 17 (14) 157 18 (13) 121
Expressed sequence 22 (2) 1,591 31 (7) 1,127
Higher-confidence categories 1,116 (136) 188 755 (229) 149
All categories 1,177 (156) 2,610 854 (270) 1,759
Columns 1 and 3 provide the number of locus projections in the PTI set that overlap Sanger genes for chromosomes 20 and 22, respectively. The 
numbers given in parentheses indicate the number of Sanger-annotated pseudogenes; these pseudogenes were not used when summarizing the 
results. Columns 2 and 4 give the number of genes in the PTI set that were not overlapping Sanger genes.R73.6 Genome Biology 2004,     Volume 5, Issue 10, Article R73       Schadt et al. http://genomebiology.com/2004/5/10/R73
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over all transcripts in our PTI leads to a false-positive rate of
3% (11 out of 406). Because we cannot exclude the possibility
that some of the transcripts supported by a single gene model
represent real genes, we consider this false-detection rate as
an upper bound on the actual false-positive rate. Accepting
that the Sanger annotations represent the gold standard for
chromosome 22, we detected 70% of all Sanger-annotated
genes, while only 4% of the chromosome 22 locus projections
that did not intersect Sanger genes were detected by our pro-
cedure, highlighting the sensitivity and specificity of this
approach. In addition, the enrichment for EVG detections in
Sanger genes versus the non-Sanger PTI on chromosomes 20
and 22 was extremely significant with a p-value effectively
equal to 0 when using the chi-square test for independence
(χ2 = 3,093, with 1 degree of freedom (df)).
Summarizing EVG data over the entire genome and assessing
the discovery potential. The last column of Table 2 provides
the number of expression verified genes detected over the
entire genome for locus projections in our PTI. This repre-
sents the most comprehensive direct experimental screening
of ab initio gene predictions ever undertaken. We can use the
false-positive and negative rates derived above to assess the
discovery potential on that part of the genome that has not
been as extensively characterized as chromosomes 20 and 22.
First, we note that our detection rates over the genome were
similar to that given for chromosomes 20 and 22. That is, 75%
of the category 1 genes (RefSeq genes) were detected over the
entire genome, compared to 80% for chromosomes 20 and
22. In total, 15,642 genes in the PTI were experimentally val-
idated using this array-based approach. Assuming the false-
positive rate of 3% defined above and a conservative false-
negative rate of 30%, defined as the percentage of Sanger
genes we failed to detect on chromosomes 20 and 22, these
data suggest there are close to 21,675 potential coding genes
represented in our PTI set. Because our PTI misses close to
10% of the Sanger genes, we corrected this number for those
genes not represented in this set and provide an estimate of
the total number of protein-coding genes in the human
genome supported by our data to be approximately 25,000.
This number is consistent with estimates given in the current
release (22.34d.1) of the Ensembl database [28,29].
However, we caution that the estimate provided is based
solely on the data described here, and that orthogonal sources
of data [30] continue to suggest that the actual number of
genes will be known only after the transcriptome has been
completely characterized.
From Table 2 we note that 2,093 (1,428 + 555 + 110) of the
transcripts that were detected as EVGs had only one line of
evidence (EST alignment, protein alignment or ab initio pre-
diction). These 2,093 transcripts represent a rich source of
potential discoveries in our PTI. To assess the potential bio-
Table 2
Summary of expression-validated genes (EVGs) from predicted transcripts over the entire human genome
Gene categories Sanger/PTI 
chromosome 20
Non-Sanger PTI 
chromosome 20
Sanger/PTI 
chromosome 22
Non-Sanger PTI 
chromosome 22
PTI genome-wide
Total Sanger genes 
represented
1,177 (826) 854 (575)
RefSeq 676 (552) 8 (2) 375 (290) 12 (5) 10,720 (7992)
Ab initio + expressed 
sequence + protein
336 (229) 10 (2) 285 (202) 10 (5) 8,801 (4269)
Ab initio + expressed 
sequence
38 (17) 96 (8) 28 (15) 74 (8) 3,733 (784)
Ab initio + protein 28 (9) 37 (7) 31 (16) 29 (4) 1,983 (233)
Expressed sequence + 
protein
38 (2) 37 (2) 36 (10) 24 (4) 1,126 (271)
Expressed sequence 22 (3) 1,591 (44) 31 (3) 1,127 (33) 7,170 (1428)
Ab initio 22 (12) 674 (39) 50 (35) 362 (17) 16,822 (555)
Protein 17 (2) 157 (7) 18 (4) 121 (4) 540 (110)
High-confidence 
categories
1,116 (809) 188 (21) 755 (533) 149 (26) 26,363 (13,549)
All categories 1,177 (826) 2,610 (111) 854 (575) 1,759 (80) 50,895 (15,642)
Columns 1 and 3 provide the total number of Sanger genes for each category for chromosomes 20 and 22, respectively, with the number of EVGs 
detected given in parentheses. Columns 2 and 4 provide the total number of LPs that did not overlap Sanger genes, with the number of EVGs 
detected given in parentheses. The last column provides the total number of LPs in the PTI represented on the PTA microarrays, with the number of 
EVGs detected over the entire genome given in parentheses.http://genomebiology.com/2004/5/10/R73 Genome Biology 2004,     Volume 5, Issue 10, Article R73       Schadt et al. R73.7
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logical functions of this novel gene set, we annotated transla-
tions of this set by searching the domains represented in the
Protein Families database (Pfam) [31]. The search results
were used to assign each of the translations to Gene Ontology
(GO) [32] codes as described in the methods. Figure 2 graph-
ically depicts the breakdown of the most common GO codes
for two of the three major GO categories. These data suggest
there may still be a significant number of protein-coding
genes with important biological functions, given that
domains/motifs represented in these predicted genes are
similar to those found in known genes. The 339 predictions
that were validated as EVGs and that had protein domains of
biological interest would be natural candidates for full-length
cloning, over the 24,532 (7,170 + 16,822 + 540 from Table 2)
other lower-confidence predictions in our set.
EVG data as an expression index
Because multiple probes in each of the approximate 50,000
predicted genes in the human genome have been monitored
over 60 different tissues and cell lines, the EVG data repre-
sent a significant atlas of human gene expression that is now
publicly available [19]. For each transcript, the intensity
information from the corresponding probes was optimally
combined as described by Johnson et al. [21] to provide a
quantitative measure of the relative abundance across the
panel of 60 conditions, as shown in Figure 3.
Tiling arrays for chromosomes 20 and 22
To complement the use of PTI arrays, we constructed a set of
genome tiling arrays comprised of 60 mer oligonucleotide
probes tiled in 30 base-pair steps through both strands of
human chromosomes 20 and 22. Repetitive sequences iden-
tified by RepeatMasker were ignored for probe design. These
genome tiling arrays allow for an unbiased view of the tran-
scriptional activity outside of known and predicted genes on
these two chromosomes. mRNA from six (chromosome 20)
or eight (chromosome 22) conditions was amplified and
hybridized to the tiling arrays (see [19] and Additional data
files 3 and 4). As with the PTI arrays, the amplification proto-
col generated strand-specific cDNA copies of the transcripts,
which were full-length. Using a two-step procedure, the
resulting data were analyzed to detect sequences expressed in
at least one condition [33]. First, we examined probe behavior
over conditions in overlapping windows of size 15,000 bp to
identify windows that probably contained transcribed
sequences, using a robust principal component analysis
(PCA) method [33]. Second, for regions identified as likely to
contain transcribed sequences, we attempted to discriminate
between probes corresponding to expressed sequences
(expressed 'exons') and probes corresponding to untran-
scribed sequences ('introns' or intergenic sequence) using a
clustering procedure on variables derived from the PCA pro-
cedure [33]. All analysis results derived from this procedure
were interpreted in the light of the Sanger annotations and
our custom PTI set described above.
Figure 4 provides two representative examples of tiling data
for two known Sanger genes, KDELR3 and EWRS1. In the
first case (Figure 4a), the tiling data almost perfectly corre-
spond to the RefSeq annotation of KDELR3, with just two
potential false positives out of the 178 intron probes. The
KDELR3 gene is annotated as having two alternative tran-
scripts in the RefSeq database, given by the RefSeq accession
numbers NM_006855 and NM_016657. The NCBI Acembly
alternative splicing predictions further suggest the presence
of additional isoforms of this gene (see Figure 4). One of the
alternative forms, KDELR3.e, depicted in Figure 4a, includes
a novel 5' exon. The presence of this exon is supported by the
EST with GenBank accession number BM921831. The tiling
data for the KDELR3 gene in two conditions clearly show
expression of NM_006855 but not NM_016657, thereby reli-
ably detecting distinct splice forms. Further, there is a signif-
icant signal 5' to exon 2 in both transcripts that seems to
suggest a novel exon, as opposed to a true false positive. This
putative exon exactly matches the location of the first exon
given in the Acembly prediction track noted in Figure 4a
(KDELR3.e).
Figure 4b shows the tiling data for the EWSR1 gene. In con-
trast to the first example, this gene has intense transcriptional
activity outside of the annotated exons. Specifically, the
EWSR1 gene has 43 potentially false-positive calls out of 203
intron probes. However, the EST data and alternative splicing
predictions strongly suggest that these probes represent bio-
logically relevant transcriptional activity. As with the
KDELR3 gene, EWRS1 is annotated by RefSeq as having two
transcripts: NM_005243 and NM_013986. The Acembly
predictions identify four additional alternative splice forms;
most noteworthy among these are EWSR1.b and EWSR.g,
shown in Figure 4b. These predictions indicate that
alternative transcripts may exist for the EWSR1  gene that
essentially divide the largest transcript into two transcripts,
suggesting that multiple promoter and transcription-stop sig-
nals are present in this gene. The tiling data depicted in Fig-
ure 4b shows that all exons from both RefSeq splice forms
were detected. In addition, there is a region to the right of
probe position 400 in Figure 4b that indicates significant
transcription activity but where there are no RefSeq exons
annotated. However, the green bars indicate exons that are
supported by EST data as well as the EWSR.b and EWSR.g
predicted alternative splice forms, providing experimental
support that these predictions represent actual isoforms of
this gene. In fact, these data may provide a more accurate rep-
resentation of the putative structure of this gene, as they sup-
port multiple alternatively spliced transcripts in this gene,
beyond what has already been annotated in the RefSeq data-
base. In all, 5% of the probes detected as expressed in intronic
sequence mapped to predicted alternative splice forms. Given
the extent of alternative splicing that is yet to be characterized
[21], we believe a significant proportion of the 'intron' tran-
scriptional activity in our data may represent alternative
splicing.R73.8 Genome Biology 2004,     Volume 5, Issue 10, Article R73       Schadt et al. http://genomebiology.com/2004/5/10/R73
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Gene Ontology (GO) classification of novel expression-validated genes (EVGs) Figure 2
Gene Ontology (GO) classification of novel expression-validated genes (EVGs). EVGs not supported by the expressed sequence data (2,093) were 
submitted to a search against the Pfam database. Those with significant alignments (339) were assigned GO codes based on Pfam. The pie charts show the 
distribution of GO terms within this set of EVGs. Note that the total number of GO terms in each category is greater than the number of EVGs because 
of assignment of multiple GO terms to some EVGs. (a) Distribution of the different 'biological process' GO codes assigned to the EVGs with significant 
hits to the Pfam database: a total of 526 GO terms. (b) Distribution of the different 'molecular function' GO codes assigned to the EVGs with significant 
hits to the Pfam database: a total of 374 GO terms.
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Summarizing the tiling results
Our genome tiling arrays consisted of 2,119,794 and
1,201,632 probes for chromosomes 20 and 22, respectively.
Of these, 1,615,034 probes fell into Sanger gene regions, with
239,542 probes actually overlapping Sanger exons. Under
stringent criteria 64,241 probes were detected as expressed,
with 34,245 of these falling within Sanger exons, 18,551 fall-
ing within Sanger introns, and 15,835 probes falling com-
pletely outside all Sanger annotations. This widespread
transcriptional activity outside annotated regions of the
human genome is consistent with other reports from multiple
species [10,12,15,16]. Overall, at least one exon in each of 876
Sanger genes was detected as expressed out of 1,703 total
genes covered by probes (excluding annotated pseudogenes),
leading to an overall gene detection rate of 52%. The bias of
probes identified as exon probes that actually fall in exons is
striking, given that exons comprise roughly 2% of the
genomic sequence (the p-value for this enrichment using the
Fisher exact test is less than 10-15). To estimate the upper
bound of false-positive calls, we counted as false-positive
events each probe identified as expressed by the detection
process, but falling within an annotated intron of the RefSeq
genes we detected as expressed. This resulted in an estimated
false-positive rate of 1.3%.
As indicated in Figure 4, a percentage of these false-positive
calls will be due to unannotated isoforms of genes. Others still
will be due to cross-hybridization of the intron probes to
genes in other parts of the genome. We consider cross-
hybridization as made up of two components: specific cross-
hybridization resulting from transcripts with similar, usually
homologous, sequences; and nonspecific cross-hybridization
resulting from the base composition of the probe sequence
(J.C. and G.C., unpublished work). Of the intron probes
detected as expressed, 23% had sequence similarities to
known transcripts considered to render them susceptible to
specific cross-hybridization, and 17% contained sequence fea-
tures associated with nonspecific cross-hybridization.
Accounting for probes that were positive for both specific and
nonspecific cross-hybridization, we are left with 55% of the
Utilizing PTA data as an expression index Figure 3
Utilizing PTA data as an expression index. Absolute transcript abundance over the 60 conditions described in [19] for two expression-supported 
transcripts. RLP09885002 represents a known gene (ATP1A1, ATPase, Na+/K+ transporting, alpha 1 polypeptide) whereas RLP10406004 was supported 
solely by gene model predictions before microarray validation.
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probes detected as expressed in the introns of Sanger genes
that cannot easily be explained as alternative splicing or
cross-hybridization. These data support recent observations
that significant levels of transcription exist within the introns
of known genes [15,16].
For those probes falling outside all Sanger genes, we again
made use of our custom genome annotations to help interpret
the extent of transcriptional activity in these regions. Table 3
summarizes the detections made for each of the categories
described above. Filtering probes using the same cross-
hybridization predictors described above suggests that 65%
of those probes falling outside all annotations are not likely to
be the result of cross-hybridization. Furthermore, for those
detections that overlap low-confidence locus projections in
our PTI, we used the classification procedure discussed above
Examples of tiling results for known genes Figure 4
Examples of tiling results for known genes. The colored bars across the bottom of the data window are color matched with the corresponding exon 
annotations shown in the genome viewer. (a) The KDELR3 gene shows strong agreement between the public transcript annotations and the tiling results. 
The top panel represents a screen shot from the UCSC genome browser [60] highlighting KDLER3. The bottom panel represents transcription activity as 
raw intensities (y-axis) for each probe used to tile through KDLER3 (x-axis), in one of the eight conditions monitored by the genomic tiling arrays. (b) The 
EWRS1 gene potentially contains a larger number of false-positive predictions, but more probably lends additional experimental support to previously 
predicted alternative splice forms (EWSR.b and EWSR.g), giving a more accurate representation of the putative structure of this gene. The top panel 
represents a screen shot from the UCSC genome browser [60] highlighting EWRS1. The bottom panel represents transcription activity as raw intensities 
(y-axis) for each probe used to tile through EWSR1 (x-axis), in one of the eight conditions monitored by the genomic tiling arrays. (c) Conserved regions 
between mouse and human upstream of the beta-actin gene. The tiling data readily detect all of the transcribed parts of the gene, but not the conserved 
regulatory regions. The green bars in the probe-intensity plot represent the annotated transcribed regions for the beta-actin gene, while the blue bars 
indicate regions that are not known to be transcribed. The lower section shows the sequence conservation between human and mouse as obtained 
through the program rVISTA [36,61]. Conserved coding (blue peaks) and non-coding regions (red peaks) are shown where the two genomic sequences 
align with 75% identity over 100-bp windows. The rows marked ELK, ETF, and SRF show binding sites for these transcription factors predicted using 
TRANSFAC matrix models and the MATCHTM program, which are part of the rVISTA suite. The exons for the gene are shown in blue.
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to assign GO codes to these transcripts. Only seven of the 297
transcribed regions detected outside of all Sanger genes via
the tiling results (see Table 3) contained GO protein domains.
This suggests that a large fraction of the transcriptional
activity detected using tiling arrays is non-coding and of
unknown biological function [15,34].
Tiling data help classify conserved sequences between 
species
One further advantage of the tiling data is that they can be
used to discriminate between transcribed and non-tran-
scribed sequences conserved between human and mouse, or
between any other pair of species. Figure 4c highlights tiling
data under one condition for the beta-actin gene, a gene that
is constitutively expressed in all tissues and often serves as a
positive control in mRNA and protein expression experi-
ments. The genomic region containing the complete beta-
actin mRNA and 10 kilobases (kb) of genomic sequence
upstream of the transcription start, was obtained from the
mouse and human genomes, aligned using the AVID program
[35] and then fed into the rVista program [36]. From this, we
identified the conserved regions in this gene between mouse
and human, including several relevant transcription factor
binding domains that are key to the transcriptional regulation
of this gene [37-39]. As can be seen directly from the figure,
the exons are all detected as highly expressed, but none of the
conserved transcription factor regions shows activity. This
combination of expressed sequence in close proximity to con-
served regions that are not expressed (as determined by the
tiling data), offers another powerful advantage of the tiling
data in discriminating among the possible roles of conserved
sequences.
Discussion
A complete understanding of the human genome will only
come after all genes have been identified and the functions of
those genes have been determined. There has been much
recent progress in defining the human transcriptome with ab
initio methods, sequencing of EST libraries, full-length gene
cloning projects, and comparative analyses between fully
sequenced genomes of different species. However, we are still
a long way from having a comprehensive set of annotations
for the human and other genomes. There is need for new
high-throughput experimental approaches to accelerate the
process of annotating sequenced genomes in a
comprehensive and accurate fashion. Toward this goal, we
have used two microarray-based experimental approaches to
provide evidence of widespread transcription activity outside
of any known or predicted genes in the human genome. We
Table 3
Summary of transcription activity detected from the chromosome 20 and 22 genome tiling data
Locus projection categories Sanger tiling 
chromosome 20
Non-Sanger tiling 
chromosome 20
Sanger tiling 
chromosome 22
Non-Sanger tiling 
chromosome 22
Total Sanger genes 1,278 933
Sanger category 1 577 (398) 368 (184)
Sanger category 2 155 (32) 121 (60)
Sanger category 3 338 (150) 144 (52)
Sanger category 4 161 (117) 294 (138)
RefSeq 3 0
Ab initio + expressed sequence + 
protein
10
Ab initio + expressed sequence 15 8
Ab initio + protein 6 4
Expressed sequence + protein 4 1
Ab initio 71 26
protein 11 21
Expressed sequence 80 46
Outside all annotations* 1,936 1,058
High-confidence categories NA 25 NA 12
All annotation categories 1,231 (697) 191 927 (434) 106
*Number of probes detected as components of EVGs. Columns 1 and 3 provide the number of Sanger genes represented on the genome tiling 
arrays for chromosomes 20 and 22, respectively, with the number of genes detected given in parentheses. Columns 2 and 4 provide the number of 
LPs not overlapping Sanger genes that were detected on chromosomes 20 and 22, respectively. NA, not applicable.R73.12 Genome Biology 2004,     Volume 5, Issue 10, Article R73       Schadt et al. http://genomebiology.com/2004/5/10/R73
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have also provided experimental support for many ab initio
predicted genes that have no other or minimal experimental
sequence support, suggesting a small but significant class of
genes that have evaded all other forms of experimental detec-
tion. Similar identifications have been made recently in the
first extensive comparative analysis between mouse and
human genomes [18]. Despite the extent of novel discovery,
our data suggest there are only 25,000-30,000 protein-cod-
ing genes in the human genome, with perhaps an equal
number of non-coding transcripts that may serve important
regulatory roles [34,40]. Finally, our data indicate wide-
spread alternative splicing across known genes, providing a
glimpse into the extent of transcript complexity that may exist
in mammalian genomes.
We have used the expression data for the approximate
50,000 predicted transcripts hybridized to 60 diverse condi-
tions in combination with genomic tiling data to generate a
CTI containing 28,456 experimentally supported transcripts.
The transcripts represented in the CTI include all
computational predictions with two or more lines of evidence
from our PTI (independent of microarray validation), in addi-
tion to the overlapping set of 15,642 transcripts detected as
EVGs. This resulting comprehensive list of known and pre-
dicted transcripts provides the starting point for large-scale
systematic studies to determine the biological function of
genes in both normal and disease states. The primary goal of
the CTI is to allow researchers to focus experimental efforts
on a comprehensive set of genes that are likely to be real.
It is of note that between the time the predicted transcript
arrays were designed and annotated using the custom
genome annotations described above, and the time this work
was published, more than 6,000 genes were added to the Ref-
Seq collection. These newer RefSeq genes were represented
by 5,100 locus projections in our original PTI that were not
classified in the RefSeq category. Interestingly, 4,212 were
detected as EVGs in the present analysis and had already been
included in our CTI, a validation rate slightly greater than
82%. Only 19% of the non-RefSeq genes in our PTI had been
detected as EVGs (see Table 2), yet more than 82% of the new
RefSeq genes coming from this set were detected as EVGs.
This result speaks to the utility of the microarray-based
approach to gene validation described here (see Additional
data file 5 for a complete breakdown of validation rates by
category).
While using microarrays to test computational gene predic-
tions experimentally has the advantage of being economically
feasible across the whole genome, the tiling data represent a
more comprehensive and unbiased view of transcription. Our
data indicate widespread transcriptional activity in the
introns of annotated genes and in intergenic regions, where a
significant proportion of this activity can be explained by
nonspecific and specific cross-hybridization. The transcrip-
tional activity noted for our low-onfidence transcripts in the
PTI indicates that 25% of the activity we observe may be cod-
ing for proteins that are at least somewhat related to existing
protein data. Much of the transcription activity we have noted
in the introns of genes may also represent uncharacterized
alternative splicing, and potentially novel genes, in addition
to specific and nonspecific cross-hybridization.
Conclusions
At present, predicted transcript arrays allow for the discovery
of most protein-coding genes genome wide when many differ-
ent conditions are considered. Until the discovery and
characterization of these protein-coding genes is completed,
this method will continue to be a cost-effective solution to
drive such discovery. In contrast, genomic tiling represents a
completely unbiased method for monitoring transcriptional
activity in genomes, but due to cost will probably be limited to
screening a smaller number of conditions. However, as novel
transcription regions are identified from the tiling data, these
regions can be represented on predicted transcript arrays that
are hybridized over many more conditions, as described in
Figure 1. As the microarray technologies have evolved, tiling
the entire human genome is now possible, with such efforts
presently being supported by the ENCODE (Encyclopedia of
DNA Elements) project of the National Human Genome
Research Institute (NHGRI) [41].
We believe the steps taken here are necessary for querying all
potential transcription activity in the genome, for the purpose
of identifying novel genes, more completely characterizing
existing genes, and identifying a more comprehensive set of
probes for these genes that can be used to monitor
transcription abundances in more standard gene expression
studies. Not all uses of microarrays demand an exhaustive
representation of probes to all genes in the genome under
study. However, experiments that seek to identify key drivers
of pathways [42] or that seek to discriminate between alterna-
tive splice forms of genes within a given tissue [21] require a
more comprehensive set of arrays to ensure success. These
data provide an essential first step to generating a compre-
hensive set of arrays that are based on experimental support
combined with computational annotation, instead of relying
solely on the latter. These comprehensive arrays will be inval-
uable as we seek to better understand mechanisms of action
for existing and novel drug targets and elucidate pathways
underlying complex diseases. In addition, further study of the
extensive noncoding RNA identified via the methods
described here and elsewhere [10,12,15,16] is likely to open
new fields of biology as the functional roles for these entities
are determined.
Materials and methods
Data preparation
The NCBI 8/2001 assembly of the human genome was the
input data for this analysis. The 4/21/1999 release of Repeat-http://genomebiology.com/2004/5/10/R73 Genome Biology 2004,     Volume 5, Issue 10, Article R73       Schadt et al. R73.13
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Masker [43] was used to mask for human repeats. An internal
database of RNA genes and bacterial and vector sequences
was aligned to the genome with BLASTN. Genomic sequences
w i t h  9 5 %  o r  h i g h e r  i d e n t i t y  o v e r  a t  l e a s t  5 0  b a s e s  w e r e
masked. No probes were designed from masked regions.
Gene index production
To predict genes on the basis of expressed sequence similar-
ity, we first clustered and aligned all expressed human and
mouse sequences in GenBank to create a human gene index
(HGI) and a mouse gene index (MGI). Clustering and align-
ment were performed with the DoubleTwist Clustering and
Alignment Tools (CAT) [44]. Input data included all mouse
and human RefSeq mRNA sequences, and EST and mRNA
sequences from GenBank release 124, masked as described
above for repeats and contaminating sequences. For each
species, the CAT software first clustered sequences and then
defined subclusters on the basis of a multiple sequence align-
ment. The subclusters represent candidate alternatively
spliced gene transcripts. The 644,168 human and 291,656
mouse sequences that were singleton ESTs or completely
masked were excluded from the HGI and MGI.
Expressed sequence mapping
Human and mouse UniGene and RefSeq, MGI, and HGI
sequences were aligned with the genome first by BLASTN
2.2.1 [45], followed by refinement of intron/exon boundaries
by the sim4 algorithm (12/17/2000 release) [46]. Only the
representative sequences (Hs.seq.uniq) for each UniGene
cluster designated in the 3 August 2001/build 138 version of
the UniGene database were used in this analysis. We only
refined BLAST alignments with an E-value of less than 10-20
for human sequences and 10-8 for mouse sequences. For
human UniGene and HGI, we refined only those BLAST hits
where the target sequence showed greater than or equal to
92% identity to the genomic sequence over 75 bp. For human
RefSeq, we refined hits with greater than or equal to 95%
identity, and for MGI, RefSeq, and UniGene, we refined hits
with greater than or equal to 80% identity. These thresholds
were empirically determined to provide good sensitivity in
aligning most sequences to the genome while limiting multi-
ple alignments past those expected from paralogs present in
the human genome. In all cases percent identity was meas-
ured over 75 bp. Individual sim4 exons of questionable
confidence were then removed on the basis of percent identity
and length thresholds. All sequence databases were down-
loaded from GenBank August, 2001.
Protein sequence mapping
The GenBank nonredundant protein database (downloaded
25 August 2001) was aligned to the genomic sequence with
BLASTX 2.2.1 [45] using an E-score threshold of 10-5. Adja-
cent protein alignments from a single protein were grouped
together as a prediction whenever the protein sequence coor-
dinates of the alignments were consistent in direction and did
not significantly overlap.
Ab initio gene prediction
GrailEXP 4.0 [47], GENSCAN 1.0 [48], FGENESH [49], and
FGENESH+ [49]ab initio gene-prediction algorithms were
run independently across the entire genome assembly to aug-
ment alignment-based gene identification methods.
GrailEXP 4.0, GENSCAN 1.0, and FGENESH version 1.c were
run with default parameters for human sequence. GrailEXP
used expressed sequence evidence from RefSeq, UniGene and
DoubleTwist HGI to refine gene predictions. FGENESH+ was
run with protein sequences from BLASTX with E-score lower
than 10-5. When multiple protein alignments overlapped, all
overlapping protein sequences were clustered with BLAST-
Clust [50] and the lowest E-score hit was used by
FGENESH+.
Synthesis and analysis
Locus projections contained the union of all exons from all
overlapping predictions in a contiguous region of the chromo-
some that were derived from sequence alignments or gene-
finding algorithms. Predictions to a given strand of the
genomic sequence that overlapped by even a single nucleotide
were grouped into a single locus projection (antisense tran-
scripts were not considered in defining the locus projections).
The criteria for grouping predictions were intentionally kept
loose, given that the intent was to include as many potential
exons as possible in a given genomic region, and then use the
experimental microarray-based approach to elucidate the
actual gene structure. These merged overlapping predictions
defined the 5' and 3' ends of the locus projections. Overlap-
ping predicted exons were merged to form an exon prediction
of maximal extent. Low-quality predicted exons from sim4
alignments that contained a high percentage of A or T were
removed. We also removed sim4-predicted exons that over-
lapped two or more predicted exons from another sim4 align-
ment. Additionally, 3' sim4 and 3' or 5' FGENESH+ predicted
exons that were short and/or distant from internal predicted
exons were removed. Finally, locus projections that contained
mRNAs from RefSeq were split at the 5' end of the RefSeq
sequence.
Locus projections supported by expressed sequences alone
could be portions of 3' or 5' UTRs of genes included in the
other gene-prediction categories described in the text. To
minimize the consequences of this potential artifact, we used
a UTR filter to exclude locus projections from the expressed
sequence alone category that were within 20 kb of a locus pro-
jection supported by an ab initio gene model.
All data were loaded into a relational database to count and
categorize locus projections. At least one type of evidence was
assigned to each predicted exon for each locus projection.
Multiple types of evidence were assigned to a merged pre-
dicted exon if there was overlap between predicted exons of
different types for at least 1% of the length of the merged exon
prediction. One of the eight evidence categories discussed in
the text was assigned to each exon on the basis of the combi-R73.14 Genome Biology 2004,     Volume 5, Issue 10, Article R73       Schadt et al. http://genomebiology.com/2004/5/10/R73
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nation of types of evidence. Locus projections inherited the
highest-ranking evidence category of their constituent exons.
Evidence categories were ranked in the following order: Ref-
seq (highest); expressed sequence + protein + ab initio;
expressed sequence + ab initio; protein + ab initio; expressed
sequence + protein; ab initio alone; protein alone; expressed
sequence alone. FGENESH+ predictions were counted as
protein + ab initio. For the ab initio category, predictions
from at least two of FGENESH, GENSCAN and GrailEXP
were required to overlap in at least one exon to be merged.
Probe selection for the genome tiling and predicted 
transcript arrays
Input sequences for probe selection were masked for vector,
interspersed repeats, simple repeats, poly(A) tails,
Escherichia coli contamination and human non-coding RNA
and mitochrondrial DNA contamination using Scylla (Para-
cel). For genomic tiling arrays, 60 mer probes were then
selected from unmasked regions of both forward and reverse
complement strands at uniform 30-base intervals. For pre-
dicted transcript arrays, up to four oligonucleotide probes
were selected from the unmasked regions of each transcript
using a multistep process.
The first step in the probe-selection process was the genera-
tion of a pool of candidate probes 60 nucleotides long (60
mers), where each probe was required to fall entirely within
an exon from the set of exons under consideration. If there
were fewer than four 60 mers then all 50 mers were consid-
ered as well. If there were fewer than four 50 mers or 60 mers
then all 40 mers were considered, and so on. Stilts composed
of sequence from Saccharomyces cerevisiae were added to
the 3' ends of probes shorter than 60 nucleotides so that they
had a total length of 60 bases when printed onto the arrays.
The second step in the probe-selection process was the classi-
fication and reduction of the probe pool on the basis of base
composition and related filters. Probes were sorted into four
classes on the basis of several criteria, including A, G, C and T
content, GC content, the length of the longest homopolymeric
run and the number of A residues at the 5' end. For example,
a probe had to have GC content between 35 and 45% to be in
class 1, between 15 and 55% to be in class 2, and between 10
and 60% to be in class 3. After all classifications were made,
probes from lower-quality classes were discarded, keeping
the number of probes per gene greater than 15. In cases where
a pair of probes was overlapping by more than 50 bases, only
a single probe was chosen.
The final step in the probe-selection process identified probes
with minimal overlap, and predicted cross-hybridization and
desirable positions in the transcript sequence. Cross-hybridi-
zation prediction was based on BLAST searching of the full
collection of transcript sequences [51]. Probes with perfect
matches to transcript sequences for genes other than the one
undergoing design were discarded unless they were the only
probes available. Otherwise the probes with the weakest pre-
dicted cross-hybridization interactions were preferred.
Probes were also selected to have as little overlap as possible,
and probes located in the last 500 bp of each transcript were
discarded where possible to reduce the effects of impaired
amplification in this region [52].
All arrays included a set of standard control probes which
were used for image processing and quality control. Each
array also included 30 randomly distributed copies of each of
51 negative-control probes. These probes were selected for
their low intensities in previous human hybridizations. The
negative controls local to each experimental probe were used
for background correction. Non-control probes were added to
each array such that all probes for a given input sequence
were grouped together and ordered by their position on the
sequence.
Preparation of labeled cDNA and array hybridization
Hybridization material was generated through a random-
priming amplification procedure using primers with a ran-
dom sequence at the 3' end and fixed motif at the 5' end. This
amplification procedure has been fully described [52] and has
been optimized to generate strand-specific cDNA copies of
the mRNA transcripts that are full-length. The 60 mRNA
samples from the human tissues described in Additional data
files 2 and 3 were purchased from Clontech. The 60 mRNA
samples hybridized to the predicted transcript set of arrays
were done in duplicate with fluor reversal to systematically
correct for dye bias. For tiling hybridizations, six samples
were used for chromosome 20 arrays and eight samples for
chromosome 22. The mRNA samples hybridized to the set of
tiling arrays were not done in duplicate as the analysis carried
out on these data was intensity based, and our preliminary
data demonstrated reasonable results without performing the
tiling experiments in fluor-reverse pairs (data not shown).
Additional data files 2-4 contain the full list of samples used
for each set of arrays.
Array images were processed as described [53] to obtain
background noise, single channel intensity and associated
measurement error estimates. Expression changes between
two samples were quantified as log10 (expression ratio) where
the expression ratio was taken to be the ratio between nor-
malized, background-corrected intensity values for the two
channels (red and green) for each spot on the predicted tran-
script arrays. An independent normalization routine was car-
ried out on the tiling data as described [33] to correct for dye
biases, given the lack of technical replicates for these data.
Analysis of predicted transcript array data
Probes from each computationally determined locus were
analyzed for coordinated expression over 60 tissues by adapt-
ing an additive, probe-specific model initially developed to
estimate gene expression indices [27]. The model for a single
probe in a single sample pair is given byhttp://genomebiology.com/2004/5/10/R73 Genome Biology 2004,     Volume 5, Issue 10, Article R73       Schadt et al. R73.15
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yij = µ + φj + θi + εj,
where the yij represent the mlratio measurements for sample
pair i and probe j in the current transcriptional model, µ is the
grand mean term, φi is the probe-specific term for probe j in
the model, θi is the sample-specific term for sample i, and εj is
the probe-specific error term, which is taken to be normally
distributed with mean 0 and variance  . Given the above
representation for an observed mlratio value, the likelihood
for a single probe over N condition pairs is simply
From this, the likelihood for a given transcriptional model,
where a transcriptional model in this context is defined as a
set of probes that are adjacent to one another in the genomic
sequence and that co-regulate over a number of conditions, is
easily seen to be the product of the individual probe likeli-
hoods defined above over the M probes comprising the cur-
rent model:
The maximum likelihood estimates for the parameters of this
model are obtained using standard optimization techniques.
With the likelihood model described above, probe groups
making up a transcriptional model were formed by iteratively
considering whether neighboring probes (within a PTI mem-
ber based on genomic location) of a given probe improved the
fit of the model just described. This was determined by exam-
ining the likelihood ratio statistics between the current, best
transcriptional model with or without an additional probe
included in the model. Thresholds for the likelihood ratio test
statistic and the different model parameters were empirically
determined to minimize false-positive and false-negative
rates. False positives were estimated by the detection of PTI
members supported by only a single ab initio prediction that
fell outside annotated Sanger genes on chromosomes 20 and
22. False negatives were defined as Sanger genes on chromo-
some 20 and 22 that were not detected. Probe sets with a
maximum likelihood statistic greater than 100 and an r2 value
for fit of data to the model greater than 0.8 were considered
high-confidence candidates for EVGs.
For each high-confidence EVG candidate, probes were fur-
ther assessed by considering the number of conditions in
which the absolute intensity of the probe was seen to be sig-
nificantly above background, and the number of times the
probe was seen significantly differentially expressed.
Candidate EVGs with at least one probe that was: signifi-
cantly above background (p-value < 0.01) in at least 10% of
the samples; or significantly differentially expressed (p-value
< 0.01) in at least 10% of the condition pairs, were considered
validated.
Analysis of tiling array data
The analysis of the tiling data has been described in detail by
Ying et al. [33]. Briefly, probes were separated into 15 kb win-
dows along the genome with 7.5 kb overlap between the
windows. For each window, a robust principal component
analysis was applied to the between-sample correlation
matrix for probes in the window. Windows containing tran-
scriptional activity were characterized by comparing the dis-
tribution of the Mahalanobis distances for the probes in the
window (the Mahalanobis distance for each probe was calcu-
lated from the probe location to the center of the data in the
first dimensions of the principal component score (PCS))
space with the reference distribution calculated based on
known intron probes. Individual probes were then classified
as belonging to the transcribed unit or not on the basis of the
log of the Mahalanobis distance and an approximation of the
diagonal distance (slope) of the probe from the minimum first
PCS and median second PCS. Using these measures for dis-
tance, the probes were clustered using standard clustering
techniques as described [33].
The procedure for estimating cross-hybridization of the
probes is the subject of a separate manuscript. For the analy-
ses described in this paper, the nonspecific cross-hybridiza-
tion was estimated by the presence of motifs within the probe
sequence that were enriched in probes observed to have a
high level of nonspecific cross-hybridization. These probes
were observed to have significant intensity when hybridized
to human mRNA samples despite having no EST support and
falling in introns of well characterized genes on chromosomes
20 and 22. Specific cross-hybridization was estimated by the
minimum predicted ∆G value for hybridization of the probe to
all genes other than the intended target in the UniGene data-
base (build 157).
Annotation of EVG and tiling data
Hidden Markov model Pfam (HMMPfam) domain predic-
tions were run on six-frame translations of the PTIs using the
HFRAME software from Paracel with an E-value cutoff of
0.01 and frameshift penalty of -12. Information on Pfam [31]
domains is available [54,55]. GO terms [32] were then
assigned to each locus projection using the full set of Pfam to
GO mappings available from EBI FTP site [56]. The domain-
to-ontology mapping is a part of the larger InterPro effort on
annotating the proteome [57,58]. Multiple GO categories can
be assigned to a single element of the PTI.
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Additional data files
The following additional data is available with the online ver-
sion of this paper and at [19]. Additional data file 1 gives a
complete list of 48,614 transcripts in the PTI that were repre-
sented on the set of predicted transcript arrays. Additional
data file 2 gives a complete list of 60 tissues and cell lines
hybridized to the predicted transcript arrays. Additional data
file 3 gives a list of six tissues and cell lines hybridized to the
chromosome 20 genomic tiling arrays. Additional data file 4
lists the eight tissues and cell lines hybridized to the chromo-
some 22 genomic tiling arrays. Additional data file 5  contains
a comparison of EVG predictions with RefSeq sequences
(March 2004). Also available on our website [19] are: ratio
data and body atlas data along with the EVG status, and full
sequences for the locus projections in fasta format. All probe
sequences and expression data are available from the GEO
database [59]. The series accession numbers for the tiling and
predicted transcript arrays are GSE1097 and GSE918
respectively.
Additional data file 1 A complete list of 48,614 transcripts in the PTI that were repre- sented on the set of predicted transcript arrays A complete list of 48,614 transcripts in the PTI that were repre- sented on the set of predicted transcript arrays Click here for additional data file Additional data file 2 A complete list of 60 tissues and cell lines hybridized to the pre- dicted transcript arrays A complete list of 60 tissues and cell lines hybridized to the pre- dicted transcript arrays Click here for additional data file Additional data file 3 A list of six tissues and cell lines hybridized to the chromosome 20  genomic tiling arrays A list of six tissues and cell lines hybridized to the chromosome 20  genomic tiling arrays Click here for additional data file Additional data file 4 The eight tissues and cell lines hybridized to the chromosome 22  genomic tiling arrays The eight tissues and cell lines hybridized to the chromosome 22  genomic tiling arrays Click here for additional data file Additional data file 5 A comparison of EVG predictions with RefSeq sequences A comparison of EVG predictions with RefSeq sequencesP Click here for additional data file
Acknowledgements
We thank D. Kessler, M. Marton and the rest of the Rosetta Gene Expres-
sion Laboratory for sample preparation and hybridization, S. Dow for
reagent and primer handling, and E. Coffey and the Array Production Team
for array synthesis. We also thank M. Krolewski and S. Ezekiel for database
and programming support. Finally, we would like to thank B. Bush and J.
Sachs for critical evaluation of the manuscript. The authors thank J. Bur-
chard for mapping the PTI probes to the current RefSeq sequences. Rosetta
Inpharmatics LLC is a wholly owned subsidiary of Merck & Co, Inc.
References
1. Liang F, Holt I, Pertea G, Karamycheva S, Salzberg SL, Quackenbush
J:  Gene index analysis of the human genome estimates
approximately 120,000 genes. Nat Genet 2000, 25:239-240.
2. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J,
Devon K, Dewar K, Doyle M, FitzHugh W, et al.: Initial sequencing
and analysis of the human genome. Nature 2001, 409:860-921.
3. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith
HO, Yandell M, Evans CA, Holt RA, et al.: The sequence of the
human genome. Science 2001, 291:1304-51.
4. Ewing B, Green P: Analysis of expressed sequence tags indi-
cates 35,000 human genes. Nat Genet 2000, 25:232-234.
5. Adams MD, Kerlavage AR, Fleischmann RD, Fuldner RA, Bult CJ, Lee
NH, EF Kitrkness, Weinstock KG, Gocayne JD, White O, et al.: Ini-
tial assessment of human gene diversity and expression pat-
terns based upon 83 million nucleotides of cDNA sequence.
Nature 1995, 377:3-174.
6. Wright FA, Lemon WJ, Zhao WD, Sears R, Zhuo D, Wang JP, Yang
HY, Baer T, Stredney D, Spitzner J, et al.: A draft annotation and
overview of the human genome.  Genome Biol 2001,
2:research0025.1-0025.18.
7. Hogenesch JB, Ching KA, Batalov S, Su AI, Walker JR, Zhou Y, Kay
SA, Schultz PG, Cooke MP: A comparison of the Celera and
Ensembl predicted gene sets reveals little overlap in novel
genes. Cell 2001, 106:413-415.
8. Camargo AA, Samaia HP, Dias-Neto E, Simao DF, Migotto IA, Briones
MR, Costa FF, Nagai MA, Verjovski-Almeida S, Zago MA, et al.: The
contribution of 700,000 ORF sequence tags to the definition
of the human transcriptome.  Proc Natl Acad Sci USA 2001,
98:12103-12108.
9. Saha S, Sparks AB, Rago C, Akmaev V, Wang CJ, Vogelstein B, Kinzler
KW, Velculescu VE: Using the transcriptome to annotate the
genome. Nat Biotechnol 2002, 20:508-512.
10. Kapranov P, Cawley SE, Drenkow J, Bekiranov S, Strausberg RL,
Fodor SP, Gingeras TR: Large-scale transcriptional activity in
chromosomes 21 and 22. Science 2002, 296:916-919.
11. Shoemaker DD, Schadt EE, Armour CD, He YD, Garrett-Engele P,
McDonagh PD, Loerch PM, Leonardson A, Lum PY, Cavet G, et al.:
Experimental annotation of the human genome using micro-
array technology. Nature 2001, 409:922-927.
12. Yamada K, Lim J, Dale JM, Chen H, Shinn P, Palm CJ, Southwick AM,
Wu HC, Kim C, Nguyen M, et al.: Empirical analysis of transcrip-
tional activity in the Arabidopsis  genome.  Science 2003,
302:842-846.
13. Strausberg RL, Feingold EA, Klausner RD, Collins FS: The mamma-
lian gene collection. Science 1999, 286:455-457.
14. Rogic S, Mackworth AK, Ouellette FB: Evaluation of gene-finding
programs on mammalian sequences.  Genome Res 2001,
11:817-832.
15. Kampa D, Cheng J, Kapranov P, Yamanaka M, Brubaker S, Cawley S,
Drenkow J, Piccolboni A, Bekiranov S, Helt G, et al.: Novel RNAs
identified from an in-depth analysis of the transcriptome of
human chromosomes 21 and 22. Genome Res 2004, 14:331-342.
16. Rinn JL, Euskirchen G, Bertone P, Martone R, Luscombe NM, Hart-
man S, Harrison PM, Nelson FK, Miller P, Gerstein M, et al.: The
transcriptional activity of human chromosome 22. Genes Dev
2003, 17:529-540.
17. Tjaden B, Saxena RM, Stolyar S, Haynor DR, Kolker E, Rosenow C:
Transcriptome analysis of Escherichia coli using high-density
oligonucleotide probe arrays.  Nucleic Acids Res 2002,
30:3732-3738.
18. Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal
P, Agarwala R, Ainscough R, Alexandersson M, An P, et al.: Initial
sequencing and comparative analysis of the mouse genome.
Nature 2002, 420:520-562.
19. Supporting online material for: A comprehensive transcript
index of the human genome generated using microarrays
and computational approaches  [http://pubinfo.rii.com/
CTI_BodyAtlas]
20. Riley JL, Mao M, Kobayashi S, Biery M, Burchard J, Cavet G, Gregson
BP, June CH, Linsley PS: Modulation of TCR-induced transcrip-
tional profiles by ligation of CD28, ICOS, and CTLA-4
receptors. Proc Natl Acad Sci USA 2002, 99:11790-11795.
21. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour
CD, Santos R, Schadt EE, Stoughton R, Shoemaker DD: Genome-
wide survey of human alternative pre-mRNA splicing with
exon junction microarrays. Science 2003, 302:2141-2144.
22. Pruitt KD, Maglott DR: RefSeq and LocusLink: NCBI gene-cen-
tered resources. Nucleic Acids Res 2001, 29:137-140.
23. Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M,
Stavrides G, Almeida JP, Babbage AK, Bagguley CL, et al.: The DNA
sequence and comparative analysis of human chromosome
20. Nature 2001, 414:865-871.
24. Collins JE, Goward ME, Cole CG, Smink LJ, Huckle EJ, Knowles S, Bye
JM, Beare DM, Dunham I: Reevaluating human gene annotation:
a second-generation analysis of chromosome 22. Genome Res
2003, 13:27-36.
25. Claverie JM: Computational methods for the identification of
genes in vertebrate genomic sequences. Hum Mol Genet 1997,
6:1735-1744.
26. Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Brusk-
iewich R, Beare DM, Clamp M, Smink LJ, et al.: The DNA sequence
of human chromosome 22. Nature 1999, 402:489-495.
27. Li C, Wong WH: Model-based analysis of oligonucleotide
arrays: expression index computation and outlier detection.
Proc Natl Acad Sci USA 2001, 98:31-36.
28. Ensembl Genome Browser  [http://www.ensembl.org/
Homo_sapiens]
29. Hubbard T, Barker D, Birney E, Cameron G, Chen Y, Clark L, Cox T,
Cuff J, Curwen V, Down T, et al.: The Ensembl genome database
project. Nucleic Acids Res 2002, 30:38-41.
30. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Waka-
matsu A, Hayashi K, Sato H, Nagai K, et al.: Complete sequencing
and characterization of 21,243 full-length human cDNAs. Nat
Genet 2004, 36:40-45.
31. Pfam home (St Louis)  [http://pfam.wustl.edu]
32. Gene Ontology Consortium  [http://www.geneontology.org]
33. Ying L, Schadt EE, Holder SVD, Edwards S, Guhathakurta D: Identi-
fication of chromosomal regions containing transcribed
sequences using microarray expression data. In 2003 Proceed-
ings of the American Statistical Association Alexandria, VA: American Sta-
tistical Association; 2003:4672-4677. 
34. Cawley S, Bekiranov S, Ng HH, Kapranov P, Sekinger EA, Kampa D,
Piccolboni A, Sementchenko V, Cheng J, Williams AJ, et al.: Unbiasedhttp://genomebiology.com/2004/5/10/R73 Genome Biology 2004,     Volume 5, Issue 10, Article R73       Schadt et al. R73.17
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
Genome Biology 2004, 5:R73
mapping of transcription factor binding sites along human
chromosomes 21 and 22 points to widespread regulation of
noncoding RNAs. Cell 2004, 116:499-509.
35. Bray N, Dubchak I, Pachter L: AVID: a global alignment
program. Genome Res 2003, 13:97-102.
36. Loots GG, Ovcharenko I, Pachter L, Dubchak I, Rubin EM: rVista for
comparative sequence-based discovery of functional tran-
scription factor binding sites. Genome Res 2002, 12:832-839.
37. Treisman R, Marais R, Wynne J: Spatial flexibility in ternary com-
plexes between SRF and its accessory proteins. EMBO J 1992,
11:4631-4640.
38. Kawamoto T, Makino K, Niwa H, Sugiyama H, Kimura S, Amemura M,
Nakata A, Kakunaga T: Identification of the human beta-actin
enhancer and its binding factor. Mol Cell Biol 1988, 8:267-272.
39. Frederickson RM, Micheau MR, Iwamoto A, Miyamoto NG: 5' flank-
ing and first intron sequences of the human beta-actin gene
required for efficient promoter activity. Nucleic Acids Res 1989,
17:253-270.
40. Storz G: An expanding universe of noncoding RNAs. Science
2002, 296:1260-1263.
41. National Human Genome Research Institute - Encyclopedia
of DNA Elements (ENCODE)  [http://www.genome.gov/
10005107]
42. Schadt EE, Monks SA, Drake TA, Lusis AJ, Che N, Colinayo V, Ruff
TG, Milligan SB, Lamb JR, Cavet G, et al.: Genetics of gene expres-
sion surveyed in maize, mouse and man.  Nature 2003,
422:297-302.
43. Repeat Masker  [http://ftp.genome.washington.edu/RM/RepeatMas
ker.html]
44. Burke J, Davison D, Hide W: d2_cluster: a validated method for
clustering EST and full-length cDNAsequences. Genome Res
1999, 9:1135-1142.
45. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lip-
man DJ: Gapped BLAST and PSI-BLAST: a new generation of
protein database search programs.  Nucleic Acids Res 1997,
25:3389-3402.
46. Florea L, Hartzell G, Zhang Z, Rubin GM, Miller W: A computer
program for aligning a cDNA sequence with a genomic DNA
sequence. Genome Res 1998, 8:967-974.
47. Xu Y, Uberbacher EC: Automated gene identification in large-
scale genomic sequences. J Comput Biol 1997, 4:325-338.
48. Burge C, Karlin S: Prediction of complete gene structures in
human genomic DNA. J Mol Biol 1997, 268:78-94.
49. Salamov AA, Solovyev VV: Ab initio gene finding in Drosophila
genomic DNA. Genome Res 2000, 10:516-522.
50. Standalone BLAST Additions|Fall/Winter
[http:www.ncbi.nlm.nih.gov/Web/Newsltr/FallWinter2000/stan
dalone.html]
51. Hughes TR, Mao M, Jones AR, Burchard J, Marton MJ, Shannon KW,
Lefkowitz SM, Ziman M, Schelter JM, Meyer MR, et al.: Expression
profiling using microarrays fabricated by an ink-jet oligonu-
cleotide synthesizer. Nat Biotechnol 2001, 19:342-347.
52. Castle J, Garrett-Engele P, Armour CD, Duenwald SJ, Loerch PM,
Meyer MR, Schadt EE, Stoughton R, Parrish ML, Shoemaker DD, et al.:
Optimization of oligonucleotide arrays and RNA amplifica-
tion protocols for analysis of transcript structure and alter-
native splicing. Genome Biol 2003, 4:R66.
53. Roberts CJ, Nelson B, Marton MJ, Stoughton R, Meyer MR, Bennett
HA, He YD, Dai H, Walker WL, Hughes TR, et al.: Signaling and
circuitry of multiple MAPK pathways revealed by a matrix of
global gene expression profiles. Science 2000, 287:873-880.
54. Pfam home page  [http://www.sanger.ac.uk/Software/Pfam]
55. Bateman A, Coin L, Durbin R, Finn RD, Hollich V, Griffiths-Jones S,
Khanna A, Marshall M, Moxon S, Sonnhammer EL, et al.: The Pfam
protein families database. Nucleic Acids Res 2004, 32 Database
issue:D138-D141.
56. EBI FTP site  [ftp://ftp.ebi.ac.uk/pub/databases/GO/goa/old/
external2go]
57. InterPro: home  [http://www.ebi.ac.uk/interpro]
58. Mulder NJ, Apweiler R, Attwood TK, Bairoch A, Barrell D, Bateman
A, Binns D, Biswas M, Bradley P, Bork P, et al.: The InterPro Data-
base, 2003 brings increased coverage and new features.
Nucleic Acids Res 2003, 31:315-318.
59. Gene Expression Omnibus  [http://www.ncbi.nlm.nih.gov/geo]
60. UCSC genome browser home  [http://genome.ucsc.edu]
61. rVISTA submission  [http://www-gsd.lbl.gov/vista/rvista/sub
mit.shtml]